Physician profile
Orrin Devinsky
NPI 1679581623
$42,171.72
in general payments reported to CMS, 2019-2025
17 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.12 · 2020: $9,880 · 2021: $59.73 · 2022: $27.93 · 2023: $6,050 · 2024: $3,850 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Travel and Lodging: $1,879 · Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,912.52 |
| Travel and Lodging | $1,878.84 |
| Food and Beverage | $381.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $17,124.60 | 2024-2025 | Fintepla |
| Ucb, INC. | $9,011.54 | 2022-2025 | Fintepla |
| Eisai INC. | $7,711.00 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $6,050.00 | 2023 | |
| Zogenix INC. | $1,100.00 | 2020 | |
| Biocodex, INC. | $1,000.00 | 2020 | |
| Livanova USA, INC. | $100.00 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.22 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.90 | 2019 | |
| Abbvie INC. | $14.73 | 2022 | |
| Harmony Biosciences LLC | $14.67 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orrin Devinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.